Traphaco Holds Conference to Review 2025 Performance and Implement the 2026 Business Plan

Vice Chairman of the Board of Directors Nguyễn Phú Khánh and CEO Đào Thúy Hà co-chair the conference

Amid the profound impact of the amended Pharmaceutical Law in 2025, alongside increasingly stringent transparency requirements and deepening segmentation across distribution channels, Traphaco Joint Stock Company convened the Conference to Review 2025 Business Performance and Implement the 2026 Plan. The conference provided an opportunity to reflect on the past year’s journey while aligning strategic directions for the period ahead.

Speaking at the conference, Ms. Đào Thúy Hà, Chief Executive Officer of Traphaco, emphasized that despite numerous challenges, the Company achieved encouraging business results in 2025, with all key indicators exceeding targets. Consolidated net revenue surpassed VND 2,650 billion, completing more than 103% of the annual plan and increasing 12% year-on-year. Profit after tax reached VND 278 billion, equivalent to 104% of the plan and an 8% increase compared to the previous year. These results demonstrate Traphaco’s ability to maintain stable growth momentum amid market pressures, while reaffirming the Company’s strong management capacity and adaptability.

According to the CEO, these achievements were underpinned by the comprehensive system restructuring that Traphaco implemented decisively from early 2025. Organizational streamlining, the reconfiguration of the business system, logistics modernization, and operational efficiency improvements have enabled the Company to better control costs, cash flow, and labor productivity. More importantly, the restructuring process has established a flexible system capable of responding swiftly to market fluctuations, paving the way for the next phase of growth.

CEO Đào Thúy Hà presents Traphaco’s 2025 business performance review and orientations for 2026

One of the key highlights analyzed in depth by the CEO at the conference was quality management, which continues to be identified as a core pillar in Traphaco’s sustainable development strategy. In 2025, the Company made substantial investments in quality testing and control systems, with total investment amounting to tens of billions of Vietnamese dong. Traphaco invested in and upgraded a total of 186 modern analytical and testing instruments, directly serving quality control for raw materials, intermediates, and finished products across the system. Notably, Traphaco successfully implemented and put into stable operation the Laboratory Management System (LMS), enhancing analytical data management capacity, standardizing testing procedures, and shortening testing turnaround times.

These systematic and well-structured investments in quality management were officially recognized by the National Institute of Drug Quality Control, which awarded Traphaco a Certificate of Commendation, affirming the Company’s professional capability, quality control systems, and compliance with specialized standards. On this foundation, product registration and licensing activities in 2025 exceeded planned targets, with numerous dossiers approved on schedule, helping to accelerate time-to-market and create growth momentum for subsequent years.

The year 2025 marked Traphaco’s strong investment in quality testing and quality control systems

Building upon its strengthened quality management platform, Traphaco recorded notable achievements in research and development of new products. The premium herbal medicine segment and high-quality generic pharmaceutical segment emerged as key growth drivers, achieving growth rates of 68% and 31% year-on-year, respectively. In particular, Boganic Premium posted growth of approximately 70%, reaffirming its role as a flagship product in the premium herbal medicine segment. In the pharmaceutical segment, a number of new and high-technology products were successfully introduced to the market, gradually increasing revenue contribution and added value. In parallel, technology transfer activities were intensified, enabling Traphaco to progressively master advanced manufacturing technologies and meet increasingly stringent requirements from both the market and regulatory authorities.

Growth-supporting activities were implemented in a synchronized manner across the entire system. Multi-channel customer care initiatives continued to expand, enhancing customer experience and strengthening brand engagement. The chain pharmacy channel recorded 23% growth year-on-year and exceeded the annual plan by 17%, standing out as a bright spot amid mounting pressure on traditional pharmacy channels. In the ETC channel, Traphaco left a clear mark through the deployment of Traflon, while the Southern ETC segment exceeded its annual plan, contributing positively to overall growth.

The performance of subsidiaries continued to represent an important piece in Traphaco’s comprehensive growth picture. Traphaco New Pharmaceutical Co., Ltd. gradually stabilized its organizational structure, streamlined personnel, and strengthened its role as a distribution hub, improving logistics efficiency and service speed. Traphaco CNC exceeded its revenue targets and continued to expand and invest in new technologies, enhancing production capacity and compliance with higher standards. Traphaco Hung Yen maintained stable manufacturing operations, ensuring quality and supply schedules. Traphaco Sa Pa recorded revenue exceeding its plan, reinforcing its role in developing medicinal herbs and products derived from raw material zones. Bamepharm achieved positive growth and progressively refreshed its brand image while improving business efficiency. Alongside these efforts, Traphaco continued to operate its three-tier enterprise risk management model, ensuring compliance and transparency across the system.

The year 2025 also marked further progress in digital transformation at Traphaco. Numerous specialized software solutions supporting quality management, research, sales, and human resources were developed and put into operation. Upgrades to digital platforms, deployment of AI chatbots, electronic contracts, and data analytics applications contributed to operational optimization, enhanced decision-making, and strengthened sales capabilities throughout the organization.

These persistent efforts were further recognized through a series of prestigious awards in 2025, including Top 10 Sustainable Enterprises (CSI), CSI Star for the period 2016–2025, Outstanding Enterprise in Intellectual Property Development and Management, as well as Top 10 Prestigious Brands and Top 10 Gold-Standard Vietnamese Products for several of Traphaco’s flagship products.

Mr. Nguyễn Phú Khánh, Vice Chairman of the Board of Directors, shares Traphaco’s business orientations for 2026

Building on the results achieved and the foundations established, Mr. Nguyễn Phú Khánh, Vice Chairman of the Board of Directors, shared the Company’s orientation for 2026 at the conference. Traphaco targets growth of over 10%, leveraging the effectiveness of its established strategic pillars. Specifically, the Company aims for consolidated net revenue of VND 2,916 billion and profit after tax of VND 306 billion in 2026, corresponding to growth of approximately 10% compared to 2025, while maintaining a stable profit margin of over 10%. Traphaco will continue to adhere to its premium herbal medicine – high-quality pharmaceutical strategy, while focusing on investment in EU-GMP–compliant manufacturing facilities to meet rising market demands and expand cooperation opportunities. The Company also plans to develop a Drug Research and Development Center (R&D) to strengthen scientific research capability, new product development, and technology mastery. In addition, Traphaco will enhance production capacity and quality at its subsidiaries, streamline and optimize its distribution system, accelerate digital transformation and AI application in governance, operations, and professional activities, and invest in training and human resource development to meet the requirements of the new development phase.

Mr. Trần Túc Mã, Member of the Board of Directors and Former CEO, delivers remarks at the Conference

Sharing his thoughts at the conference, Mr. Trần Túc Mã, Member of the Board of Directors and Former Chief Executive Officer, expressed his pleasure and appreciation for the results Traphaco achieved in 2025, while conveying strong confidence in the Company’s future development. He noted that the new context of the pharmaceutical industry—with increasingly stringent requirements for quality, transparency, and compliance—represents a favorable opportunity for reputable, long-established, and well-governed enterprises like Traphaco to further assert their position. He extended his best wishes to the Board of Directors and all employees, encouraging them to continue upholding unity, resilience, and dedication, to continuously innovate and take Traphaco even further in the years ahead, while wishing the entire Traphaco family a New Year of health, peace, and success.

Concluding the conference, CEO Đào Thúy Hà officially announced Traphaco’s 2026 theme: “Execution Speed – Breakthrough Productivity”, affirming the leadership’s determination to translate strategic directions into concrete actions, enhance execution efficiency, and create strong momentum for Traphaco’s next phase of sustainable and in-depth growth.

CEO Đào Thúy Hà announces Traphaco’s 2026 theme: “Swift Execution - Breakthrough Productivity”

Một số hình ảnh tại Hội nghị:

Ms. Trần Thị Anh Phương, Deputy CEO in charge of OTC Sales, presents her report at the Conference

Mr. Kim Dong Hyu, Deputy CEO in charge of ETC Sales & Business Development, presents his report at the Conference

Mr. Phạm Hoàng Anh, Deputy CEO in charge of Finance & Planning, presents his report at the Conference

Mr. Nguyễn Huy Văn, Deputy CEO in charge of Research & Quality, presents his report at the Conference

Mr. Thái Đức Luận, Director of Traphaco Pharmaceutical One Member Limited Liability Company, presents his report at the Conference

Mr. Phan Thành Trinh, Director of Dak Lak Pharmaceutical & Medical Equipment Joint Stock Company (Bamepharm), presents his report at the Conference

Mr. Đỗ Tiến Sỹ, Director of Traphaco Sapa One Member Limited Liability Company, presents his report at the Conference

Ms. Phạm Thị Thanh Duyên, Director of Traphaco Hung Yen Limited Liability Company, presents her report at the Conference

Ms. Trịnh Thanh Huyền, Director of Traphaco High-Tech Joint Stock Company, presents her report at the Conference